Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: Exploratory analysis of the REAL-2 trial

Annals of Oncology

Volumn 27, Issue 4, 2016, Pages 687-692

  Grenader, T ^a   Waddell, T ^b   Peckitt, C ^c   Oates, J ^b   Starling, N ^b   Cunningham, D ^b   Bridgewater, J ^d  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ECF; ECX; EOF; EOX; Neutrophil to lymphocyte ratio; Oesophago gastric cancer

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; OXALIPLATIN; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; ESOPHAGUS CANCER; EXPLORATORY RESEARCH; FEMALE; GASTROESOPHAGEAL CANCER; HUMAN; LEUKOCYTE COUNT; LONG TERM SURVIVAL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; SURVIVAL TIME; TREATMENT RESPONSE; AGED; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; KAPLAN MEIER METHOD; LYMPHOCYTE; MIDDLE AGED; NEOADJUVANT THERAPY; NEUTROPHIL; PATHOLOGY; PROGNOSIS; STOMACH NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CAPECITABINE; CISPLATIN; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEUTROPHILS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84964655359     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw012     Document Type: Article

References (22)

1. CRUK 2015. Cancer mortality. http://www.cancerresearchuk.org/cancer-info/cancerstats/mortality/uk-cancer-mortality-statistics.
2. Chan DS, Reid TD, White C et al. Influence of a regional centralised upper gastrointestinal cancer service model on patient safety, quality of care and survival. Clin Oncol (R Coll Radiol) 2013; 25: 719-725.
3. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
5. Lee DY, Hong SW, Chang YG et al. Clinical significance of preoperative inflammatory parameters in gastric cancer patients. J Gastric Cancer 2013; 13: 111-116.
6. Templeton AJ, McNamara MG, Šeruga B et al. Prognostic role of neutrophilto-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106: dju124.
7. Zhang X, Zhang W, Feng LJ. Prognostic significance of neutrophil lymphocyte ratio in patients with gastric cancer: a meta-analysis. PLoS One 2014; 9: e111906.
8. Grenader T, Plotkin Y, Mohammadi B et al. Predictive value of the neutrophil/ lymphocyte ratio in peritoneal and/or metastatic disease at staging laparoscopy for gastric and esophageal adenocarcinoma. J Gastrointest Cancer 2015; 46: 267-271.
9. Grenader T, Nash S, Plotkin Y et al. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies. Ann Oncol 2015; 26: 1910-1916.
10. Lee S, Oh SY, Kwon HC et al. The clinical significance of neutrophil-lymphocyte ratio versus platelet-lymphocyte ratio in patients with metastatic gastric cancer. J Clin Oncol 2012; 30(suppl): abstr e14686.
11. McNamara MG, Templeton AJ, Maganti M et al. Neutrophil/lymphocyte ratio (NLR) as a prognostic factor in biliary tract cancer (BTC). J Clin Oncol 2013; 31(suppl): abstr 4130.
12. Jung MR, Park YK, Jeong O et al. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 2011; 104: 504-510.
13. Templeton AJ, Ace O, McNamara MG et al. Prognostic role of platelet-tolymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014; 23: 1204-1212.
14. Yao Y, Yuan D, Liu H et al. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother 2013; 62: 471-479.
15. McCourt M, Wang JH, Sookhai S et al. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg 1999; 134: 1325-1331.
16. McCourt M, Wang JH, Sookhai S et al. Activated human neutrophils release hepatocyte growth factor/scatter factor. Eur J Surg Oncol 2001; 27: 396-403.
17. Jablonska E, Kiluk M, Markiewitz W et al. TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. Arch Immunol Ther Exp 2001; 49: 63-69.
18. Dvorak HF. Tumors: wounds that do not heal. N Engl J Med 1986; 315: 1650-1659.
19. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in nodepositive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31: 860-867.
20. Gooden MJ, de Bock GH, Leffers N et al. The prognostic influence of tumourinfiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105: 93-103.
21. Chua W, Charles KA, Baracos VE et al. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011; 104: 1288-1295.
22. Chua W, Clarke SJ, Charles KA. Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Support Care Cancer 2012; 20: 1869-1874.